{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:05:50Z","timestamp":1789679150279,"version":"4.0.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":1075,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17K09598"],"award-info":[{"award-number":["17K09598"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["li.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Laboratory Investigation"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1038\/s41374-019-0363-1","type":"journal-article","created":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T14:03:27Z","timestamp":1577973807000},"page":"324-337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Production of TRPV2-targeting functional antibody ameliorating dilated cardiomyopathy and muscular dystrophy in animal models"],"prefix":"10.1016","volume":"100","author":[{"given":"Yuko","family":"Iwata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Kitakaze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/s41374-019-0363-1_bib1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1136\/hrt.2004.040337","article-title":"New insights into the pathology of inherited cardiomyopathy","volume":"91","author":"Hughes","year":"2005","journal-title":"Heart"},{"key":"10.1038\/s41374-019-0363-1_bib2","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1152\/physrev.00012.2002","article-title":"Molecular mechanisms of inherited cardiomyopathies","volume":"82","author":"Fatkin","year":"2002","journal-title":"Physiol Rev"},{"key":"10.1038\/s41374-019-0363-1_bib3","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0092-8674(01)00242-2","article-title":"The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms","volume":"104","author":"Seidman","year":"2001","journal-title":"Cell"},{"key":"10.1038\/s41374-019-0363-1_bib4","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(09)62023-7","article-title":"Dilated cardiomyopathy","volume":"375","author":"Jefferies","year":"2010","journal-title":"Lancet"},{"key":"10.1038\/s41374-019-0363-1_bib5","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1038\/s41374-019-0363-1_bib6","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1038\/s41374-019-0363-1_bib7","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/eurheartj\/ehs257","article-title":"Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice","volume":"33","author":"Zannad","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1038\/s41374-019-0363-1_bib8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/338259a0","article-title":"Association of dystrophin and an integral membrane glycoprotein","volume":"338","author":"Campbell","year":"1989","journal-title":"Nature"},{"key":"10.1038\/s41374-019-0363-1_bib9","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/0092-8674(95)90344-5","article-title":"Three muscular dystrophies: loss of cytoskeleton-extracellular matrix linkage","volume":"80","author":"Campbell","year":"1995","journal-title":"Cell"},{"key":"10.1038\/s41374-019-0363-1_bib10","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/CIRCRESAHA.116.309396","article-title":"Dilated cardiomyopathy: genetic determinants and mechanisms","volume":"121","author":"McNally","year":"2017","journal-title":"Circ Res"},{"key":"10.1038\/s41374-019-0363-1_bib11","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/hmg\/6.4.601","article-title":"Identification of the Syrian hamster cardiomyopathy gene","volume":"6","author":"Nigro","year":"1997","journal-title":"Hum Mol Genet"},{"key":"10.1038\/s41374-019-0363-1_bib12","doi-asserted-by":"crossref","first-page":"C690","DOI":"10.1152\/ajpcell.2001.281.2.C690","article-title":"Stretch-activated cation channels in skeletal muscle myotubes from sarcoglycan-deficient hamsters","volume":"281","author":"Nakamura","year":"2001","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1038\/s41374-019-0363-1_bib13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s004240100516","article-title":"Stretch-induced cell damage in sarcoglycan-deficient myotubes","volume":"442","author":"Sampaolesi","year":"2001","journal-title":"Pflugers Arch"},{"key":"10.1038\/s41374-019-0363-1_bib14","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1083\/jcb.200301101","article-title":"A novel mechanism of myocyte degeneration involving the Ca2+-permeable growth factor-regulated channel","volume":"161","author":"Iwata","year":"2003","journal-title":"J Cell Biol"},{"key":"10.1038\/s41374-019-0363-1_bib15","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1093\/cvr\/cvt163","article-title":"Blockade of sarcolemmal TRPV2 accumulation inhibits progression of dilated cardiomyopathy","volume":"99","author":"Iwata","year":"2013","journal-title":"Cardiovasc Res"},{"key":"10.1038\/s41374-019-0363-1_bib16","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/hmg\/ddn408","article-title":"Dominant-negative inhibition of Ca2+ influx via TRPV2 ameliorates muscular dystrophy in animal models","volume":"18","author":"Iwata","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1038\/s41374-019-0363-1_bib17","doi-asserted-by":"crossref","first-page":"14042","DOI":"10.18632\/oncotarget.24449","article-title":"Novel inhibitor candidates of TRPV2 prevent damage of dystrophic myocytes and ameliorate against dilated cardiomyopathy in a hamster model","volume":"9","author":"Iwata","year":"2018","journal-title":"Oncotarget"},{"key":"10.1038\/s41374-019-0363-1_bib18","doi-asserted-by":"crossref","first-page":"e8689","DOI":"10.15252\/emmm.201708689","article-title":"Tranilast directly targets NLRP3 to treat inflammasome-driven diseases.","volume":"10","author":"Huang","year":"2018","journal-title":"EMBO Mol Med."},{"key":"10.1038\/s41374-019-0363-1_bib19","doi-asserted-by":"crossref","first-page":"e00291","DOI":"10.1002\/prp2.291","article-title":"Uricosuric targets of tranilast","volume":"5","author":"Mandal","year":"2017","journal-title":"Pharmacol Res Perspect"},{"key":"10.1038\/s41374-019-0363-1_bib20","doi-asserted-by":"crossref","first-page":"550","DOI":"10.2183\/pjab.87.550","article-title":"Adult onset cardiac dilatation in a transgenic mouse line with Galbeta1,3GalNAc alpha2,3-sialyltransferase II (ST3Gal-II) transgenes: a new model for dilated cardiomyopathy","volume":"87","author":"Suzuki","year":"2011","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"10.1038\/s41374-019-0363-1_bib21","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1161\/CIRCRESAHA.108.175141","article-title":"Activation of Na+\/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure","volume":"103","author":"Nakamura","year":"2008","journal-title":"Circ Res"},{"key":"10.1038\/s41374-019-0363-1_bib22","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.yjmcc.2013.02.008","article-title":"Global metabolomic analysis of heart tissue in a hamster model for dilated cardiomyopathy","volume":"59","author":"Maekawa","year":"2013","journal-title":"J Mol Cell Cardiol"},{"key":"10.1038\/s41374-019-0363-1_bib23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1247\/csf.08043","article-title":"Magnetic separation of human podocalyxin-like protein 1 (hPCLP1)-positive cells from peripheral blood and umbilical cord blood using anti-hPCLP1 monoclonal antibody and protein A expressed on bacterial magnetic particles","volume":"34","author":"Kuhara","year":"2009","journal-title":"Cell Struct Funct"},{"key":"10.1038\/s41374-019-0363-1_bib24","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.bcp.2005.05.034","article-title":"Protective effects of Ca2+ handling drugs against abnormal Ca2+ homeostasis and cell damage in myopathic skeletal muscle cells","volume":"70","author":"Iwata","year":"2005","journal-title":"Biochem Pharmacol"},{"key":"10.1038\/s41374-019-0363-1_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11130","article-title":"Structure of the full-length TRPV2 channel by cryo-EM","volume":"7","author":"Huynh","year":"2016","journal-title":"Nat Commun"},{"key":"10.1038\/s41374-019-0363-1_bib26","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/B978-0-12-800181-3.00009-9","article-title":"Structure and function of the thermoTRP channel pore","volume":"74","author":"Zheng","year":"2014","journal-title":"Curr Top Membr"},{"key":"10.1038\/s41374-019-0363-1_bib27","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/19420862.2018.1548232","article-title":"Ion channels as therapeutic antibody targets","volume":"11","author":"Hutchings","year":"2019","journal-title":"MAbs"},{"key":"10.1038\/s41374-019-0363-1_bib28","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1177\/1087057114560698","article-title":"Discovery of functional antibodies targeting ion channels","volume":"20","author":"Wilkinson","year":"2015","journal-title":"J Biomol Screen"},{"key":"10.1038\/s41374-019-0363-1_bib29","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3389\/fphar.2019.00606","article-title":"Monoclonal antibodies targeting ion channels and their therapeutic potential","volume":"10","author":"Haustrate","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1038\/s41374-019-0363-1_bib30","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1177\/1087057114560698","article-title":"Discovery of functional antibodies targeting ion channels","volume":"20","author":"Wilkinson","year":"2019","journal-title":"J Biomol Screen"},{"key":"10.1038\/s41374-019-0363-1_bib31","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/19420862.2017.1386825","article-title":"Chickens with humanized immunoglobulin genes generate antibodies with high affinity and broad epitope coverage to conserved targets","volume":"10","author":"Ching","year":"2018","journal-title":"MAbs"},{"key":"10.1038\/s41374-019-0363-1_bib32","doi-asserted-by":"crossref","first-page":"594","DOI":"10.4161\/mabs.2.6.13420","article-title":"Therapeutic antibodies directed at G protein-coupled receptors","volume":"2","author":"Hutchings","year":"2010","journal-title":"MAbs"},{"key":"10.1038\/s41374-019-0363-1_bib33","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/nsmb.3159","article-title":"Cryo-electron microscopy structure of the TRPV2 ion channel","volume":"23","author":"Zubcevic","year":"2016","journal-title":"Nat Struct Mol Biol"},{"key":"10.1038\/s41374-019-0363-1_bib34","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1124\/mol.107.037044","article-title":"Pharmacological characterization and molecular determinants of the activation of transient receptor potential V2 channel orthologs by 2-aminoethoxydiphenyl borate","volume":"72","author":"Juvin","year":"2007","journal-title":"Mol Pharmacol"},{"key":"10.1038\/s41374-019-0363-1_bib35","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1124\/jpet.106.108092","article-title":"A polyclonal antibody to the prepore loop of transient receptor potential vanilloid type 1 blocks channel activation","volume":"319","author":"Klionsky","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1038\/s41374-019-0363-1_bib36","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/cvr\/cvv021","article-title":"Dystrophic cardiomyopathy: role of TRPV2 channels in stretch-induced cell damage","volume":"106","author":"Lorin","year":"2015","journal-title":"Cardiovasc Res"},{"key":"10.1038\/s41374-019-0363-1_bib37","doi-asserted-by":"crossref","first-page":"e82944","DOI":"10.1371\/journal.pone.0082944","article-title":"Antibody-mediated targeting of the Orai1 calcium channel inhibits T cell function","volume":"8","author":"Cox","year":"2013","journal-title":"PLoS One"},{"key":"10.1038\/s41374-019-0363-1_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10339","article-title":"A monoclonal antibody against KCNK9 K(+) channel extracellular domain inhibits tumour growth and metastasis","volume":"7","author":"Sun","year":"2016","journal-title":"Nat Commun"},{"key":"10.1038\/s41374-019-0363-1_bib39","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.bbamcr.2015.04.011","article-title":"Endocytosis of ABCG2 drug transporter caused by binding of 5D3 antibody: trafficking mechanisms and intracellular fate","volume":"1853","author":"Studzian","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"10.1038\/s41374-019-0363-1_bib40","doi-asserted-by":"crossref","first-page":"12254","DOI":"10.1074\/jbc.M116.722330","article-title":"Modulation of P2X3 and P2X2\/3 receptors by monoclonal antibodies","volume":"291","author":"Shcherbatko","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1038\/s41374-019-0363-1_bib41","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1097\/HJH.0000000000001213","article-title":"Transient receptor potential vanilloid 2 function regulates cardiac hypertrophy via stretch-induced activation","volume":"35","author":"Koch","year":"2017","journal-title":"J Hypertens"},{"key":"10.1038\/s41374-019-0363-1_bib42","doi-asserted-by":"crossref","first-page":"e105055","DOI":"10.1371\/journal.pone.0105055","article-title":"The transient receptor potential vanilloid 2 cation channel is abundant in macrophages accumulating at the peri-infarct zone and may enhance their migration capacity towards injured cardiomyocytes following myocardial infarction","volume":"9","author":"Entin-Meer","year":"2014","journal-title":"PLoS One"},{"key":"10.1038\/s41374-019-0363-1_bib43","doi-asserted-by":"crossref","first-page":"e0177132","DOI":"10.1371\/journal.pone.0177132","article-title":"TRPV2 knockout mice demonstrate an improved cardiac performance following myocardial infarction due to attenuated activity of peri-infarct macrophages","volume":"12","author":"Entin-Meer","year":"2017","journal-title":"PLoS One"},{"key":"10.1038\/s41374-019-0363-1_bib44","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s40520-016-0663-x","article-title":"The role of transient receptor potential vanilloid 2 channel in cardiac aging","volume":"29","author":"Jones","year":"2017","journal-title":"Aging Clin Exp Res"},{"key":"10.1038\/s41374-019-0363-1_bib45","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nri2761","article-title":"Therapeutic antibodies for autoimmunity and inflammation","volume":"10","author":"Chan","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1038\/s41374-019-0363-1_bib46","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nrc3236","article-title":"Antibody therapy of cancer","volume":"12","author":"Scott","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/s41374-019-0363-1_bib47","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2169\/internalmedicine.8651-16","article-title":"A pilot study of tranilast for cardiomyopathy of muscular dystrophy","volume":"57","author":"Matsumura","year":"2018","journal-title":"Intern Med"},{"key":"10.1038\/s41374-019-0363-1_bib48","doi-asserted-by":"crossref","first-page":"11960","DOI":"10.1021\/acsomega.9b01228","article-title":"Repurposing of tranilast for potential neuropathic pain treatment by inhibition of sepiapterin reductase in the BH4 pathway.","volume":"4","author":"Moore","year":"2019","journal-title":"ACS Omega."}],"container-title":["Laboratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41374-019-0363-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41374-019-0363-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683722012855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683722012855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41374-019-0363-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T19:38:51Z","timestamp":1758397131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0023683722012855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0023683722012855"],"URL":"https:\/\/doi.org\/10.1038\/s41374-019-0363-1","relation":{},"ISSN":["0023-6837"],"issn-type":[{"value":"0023-6837","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Production of TRPV2-targeting functional antibody ameliorating dilated cardiomyopathy and muscular dystrophy in animal models","name":"articletitle","label":"Article Title"},{"value":"Laboratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/s41374-019-0363-1","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}